Holen Sie sich die Stockscreener-App
1.49
7.97%
0.11
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Down 35.0% in May - Defense World
IO Biotech Regains Nasdaq Compliance with Stock Price - MSN
Wall Street Zen Upgrades IO Biotech (NASDAQ:IOBT) to “Sell” - Defense World
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies | DelveInsight - The Globe and Mail
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Metastatic Melanoma Pipeline Appears Robust With 20+ Key Pharma - openPR.com
IO Biotech reports annual meeting results By Investing.com - Investing.com Nigeria
IO Biotech reports annual meeting results - Investing.com India
IO Biotech Elects New Director at Annual Meeting - TipRanks
Citadel Advisors LLC Purchases Shares of 270,504 IO Biotech, Inc. (NASDAQ:IOBT) - Defense World
IO Biotech Regains Compliance With Nasdaq Listing Rules - marketscreener.com
io biotech regains nasdaq compliance after bid price recovery By Investing.com - Investing.com India
io biotech regains nasdaq compliance after bid price recovery - Investing.com
Director Heidi Hunter Acquires 15,000 Shares of IO Biotech Inc (IOBT) - GuruFocus
Stocks in play: Corus Entertainment - The Globe and Mail
Io biotech director Heidi Hunter purchases $20,884 in common stock By Investing.com - Investing.com South Africa
Io biotech director Heidi Hunter purchases $20,884 in common stock - Investing.com Australia
5 Best Microbiome Companies (June 2025) - Securities.io
Here Are My Top 3 High-Yield Pipeline Stocks to Buy Now - The Globe and Mail
Pembina Pipeline Corporation Announces Redemption of Series 19 Preferred Shares - The Globe and Mail
3 Internet Software Stocks to Buy From a Prospering Industry - The Globe and Mail
Cancer Vaccines Market Sees Boost from UK's New Injection and Korea's Cell Conversion Research - openPR.com
Dividend 15 Split Corp. II Announces TSX Acceptance of Normal Course Issuer Bid - The Globe and Mail
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? - sharewise
Beyond Lithium Completes Acquisition of Rare One Project in Southeastern British Columbia - The Globe and Mail
Targeting solid tumors two ways with one cancer vaccine - drugdiscoverynews.com
Prediction: This Will Be the First Mega Technology Company to Split Its Stock in 2025 (and It Isn't Tesla) - The Globe and Mail
Io Biotech Inc Files For Resale Of Up To 5.6 Million Shares Of Common Stock By The Selling StockholdersSEC Filing - marketscreener.com
IOBT Investors: Understanding Stockholder Sales Impact | IOBT St - GuruFocus
2 "Magnificent Seven" Stocks Billionaires Are Buying - The Globe and Mail
Elliott Waves: Dollar Index Can Be Targeting New Lows - The Globe and Mail
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference - The Manila Times
Cancer Vaccine Developer IO Biotech Headlines Two Major Healthcare Conferences This Summer - Stock Titan
Is NIO Stock Set for a Comeback? Fundamentals Say Yes - The Globe and Mail
Q2 Earnings Forecast for IO Biotech Issued By HC Wainwright - Defense World
Sustainable Success Stories: 2 U.S. Companies With a Legacy of Growth - The Globe and Mail
Why Alphabet Stock Ticked Higher Today - The Globe and Mail
IO Biotech Advances Cancer Vaccine Trials in Q1 2025 - TipRanks
IO Biotech price target raised to $14 from $12 at H.C. Wainwright - Yahoo Finance
Why American Eagle Stock Plummeted After Earnings - The Globe and Mail
IO Biotech, Inc. SEC 10-Q Report - TradingView
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
‘We’re Delivering Real Progress Toward Profitability:’ Is Plug Power Stock a Buy, Sell, or Hold After Earnings? - The Globe and Mail
IO Biotech (IOBT) Projected to Post Quarterly Earnings on Tuesday - Defense World
4 No-Brainer Stocks to Buy Right Now - The Globe and Mail
Renaissance Technologies LLC Raises Stake in IO Biotech, Inc. (NASDAQ:IOBT) - Defense World
“Horrible Things Done to Slack,” says Salesforce (NYSE:CRM) CEO Benioff about Microsoft - The Globe and Mail
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of IO Biotech, Inc. (NASDAQ: IOBT) and Encourages IOBT Shareholders to Contact the Firm - ACCESS Newswire
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):